Wealthfront Advisers LLC Grows Position in IDEXX Laboratories, Inc. $IDXX

Wealthfront Advisers LLC boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.0% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 18,602 shares of the company’s stock after acquiring an additional 1,687 shares during the quarter. Wealthfront Advisers LLC’s holdings in IDEXX Laboratories were worth $10,452,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of IDXX. Elyxium Wealth LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at $3,666,459,000. State Street Corp grew its position in IDEXX Laboratories by 4.0% during the 4th quarter. State Street Corp now owns 3,656,626 shares of the company’s stock worth $2,473,817,000 after purchasing an additional 138,956 shares during the last quarter. J. Stern & Co. LLP increased its stake in IDEXX Laboratories by 23,694.7% in the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock valued at $1,795,072,000 after purchasing an additional 2,642,200 shares during the period. Geode Capital Management LLC grew its position in IDEXX Laboratories by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock valued at $1,749,380,000 after buying an additional 86,263 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in IDEXX Laboratories by 13.8% during the fourth quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock worth $1,016,296,000 after purchasing an additional 181,955 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IDXX has been the subject of a number of analyst reports. Stifel Nicolaus cut their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. UBS Group reduced their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday. Citigroup initiated coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective for the company. Finally, Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $567.44 on Friday. The stock has a fifty day moving average price of $554.49 and a 200 day moving average price of $599.94. IDEXX Laboratories, Inc. has a 52 week low of $513.02 and a 52 week high of $769.98. The firm has a market capitalization of $44.76 billion, a P/E ratio of 41.78, a PEG ratio of 3.15 and a beta of 1.55. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the company earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.